Michalis Doumas

List of Publications by Citations

268 papers	4,940 citations	37 h-index	63 g-index
321 ext. papers	6,169 ext. citations	4.6 avg, IF	5.76 L-index

#	Paper	IF	Citations
268	Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. *Lancet, The*, **2008**, 371, 1921-6	40	364
267	A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. *Journal of Immunology*, **2006**, 177, 4794-802	5.3	344
266	Exercise capacity and mortality in older men: a 20-year follow-up study. *Circulation*, **2010**, 122, 790-7	16.7	230
265	The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. *Metabolism: Clinical and Experimental*, **2017**, 71, 17-32	12.7	152
264	Interactive effects of fitness and statin treatment on mortality risk in veterans with dyslipidaemia: a cohort study. *Lancet, The*, **2013**, 381, 394-9	40	130
263	Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. *Kidney International*, **2015**, 87, 649-59	9.9	124
262	Female sexual dysfunction in essential hypertension: a common problem being uncovered. *Journal of Hypertension*, **2006**, 24, 2387-92	1.9	107
261	Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis. *Blood*, **2010**, 116, 631-9	2.2	103
260	Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. *World Journal of Gastroenterology*, **2015**, 21, 7860-8	5.6	97
259	Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. *Nature Medicine*, **2021**, 27, 1752-1760	50.5	93
258	Factors affecting the increased prevalence of erectile dysfunction in Greek hypertensive compared with normotensive subjects. *Journal of Andrology*, **2006**, 27, 469-77		92
257	Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. *World Journal of Gastroenterology*, **2015**, 21, 6820-34	5.6	91
256	Sexual dysfunction: the Φprima ballerinaΩof hypertension-related quality-of-life complications. *Journal of Hypertension*, **2008**, 26, 2074-84	1.9	91
255	Exercise capacity and mortality in hypertensive men with and without additional risk factors. *Hypertension*, **2009**, 53, 494-9	8.5	87
254	Gender differences in hypertension: myths and reality. *Current Hypertension Reports*, **2013**, 15, 321-30	4.7	86
253	Exercise capacity and progression from prehypertension to hypertension. *Hypertension*, **2012**, 60, 333-8	8.5	83
252	Diabetes and lipid metabolism. *Hormones*, **2018**, 17, 61-67	3.1	81

251	BMI-mortality paradox and fitness in African American and Caucasian men with type 2 diabetes. *Diabetes Care*, **2012**, 35, 1021-7	14.6	77
250	Beneficial effects of switching from beta-blockers to nebivolol on the erectile function of hypertensive patients. *Asian Journal of Andrology*, **2006**, 8, 177-82	2.8	75
249	Antihypertensive treatment and sexual dysfunction. *Current Hypertension Reports*, **2012**, 14, 285-92	4.7	65
248	The effect of antihypertensive drugs on erectile function: a proposed management algorithm. *Journal of Clinical Hypertension*, **2006**, 8, 359-64	2.3	63
247	Renal sympathetic denervation and systemic hypertension. *American Journal of Cardiology*, **2010**, 105, 570-6	3	61
246	Effect of tobacco smoking and smoking cessation on plasma lipoproteins and associated major cardiovascular risk factors: a narrative review. *Current Medical Research and Opinion*, **2013**, 29, 1263-74	2.5	60
245	Dynamic resistant hypertension patterns as predictors of cardiovascular morbidity: a 4-year prospective study. *Journal of Hypertension*, **2014**, 32, 415-22	1.9	59
244	Computed Tomography and Adrenal Venous Sampling in the Diagnosis of Unilateral Primary Aldosteronism. *Hypertension*, **2018**, 72, 641-649	8.5	54
243	Effect of Intensive Versus Standard Blood Pressure Treatment According to Baseline Prediabetes Status: A Post Hoc Analysis of a Randomized Trial. *Diabetes Care*, **2017**,	14.6	53
242	Hypertension and sexual dysfunction: time to act. *Journal of Hypertension*, **2011**, 29, 403-7	1.9	50
241	Common secondary causes of resistant hypertension and rational for treatment. *International Journal of Hypertension*, **2011**, 2011, 236239	2.4	49
240	Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk. *Current Vascular Pharmacology*, **2018**, 16, 246-253	3.3	49
239	Cardiovascular risk in rheumatoid arthritis: pathogenesis, diagnosis, and management. *Journal of Clinical Rheumatology*, **2012**, 18, 422-30	1.1	47
238	Renal nerve ablation for resistant hypertension: how did we get here, present status, and future directions. *Circulation*, **2014**, 129, 1440-51	16.7	40
237	Renal denervation and Symplicity HTN-3: "Dubium sapientiae initium" (doubt is the beginning of wisdom). *Circulation Research*, **2014**, 115, 211-4	15.7	39
236	Exercise capacity and all-cause mortality in male veterans with hypertension aged ⍰0 years. *Hypertension*, **2014**, 64, 30-5	8.5	39
235	Renal sympathetic denervation: the jury is still out. *Lancet, The*, **2010**, 376, 1878-80	40	39
234	Divergent retinal vascular abnormalities in normotensive persons and patients with never-treated, masked, white coat hypertension. *American Journal of Hypertension*, **2013**, 26, 318-25	2.3	38

233	Left ventricular hypertrophy as a determinant of renal outcome in patients with high cardiovascular risk. *Journal of Hypertension*, **2010**, 28, 2299-308	1.9	37
232	Management of erectile dysfunction in hypertension: Tips and tricks. *World Journal of Cardiology*, **2014**, 6, 908-15	2.1	36
231	Exercise capacity and all-cause mortality in prehypertensive men. *American Journal of Hypertension*, **2009**, 22, 735-41	2.3	36
230	Sexual Dysfunction, Cardiovascular Risk and Effects of Pharmacotherapy. *Current Vascular Pharmacology*, **2018**, 16, 130-142	3.3	36
229	A graded association of exercise capacity and all-cause mortality in males with high-normal blood pressure. *Blood Pressure*, **2009**, 18, 261-7	1.7	33
228	Body mass index, exercise capacity, and mortality risk in male veterans with hypertension. *American Journal of Hypertension*, **2012**, 25, 444-50	2.3	31
227	Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality?. *Journal of Neurology, Neurosurgery and Psychiatry*, **2017**, 88, 249-253	5.5	30
226	Left ventricular hypertrophy in athletes and hypertensive patients. *Journal of Clinical Hypertension*, **2017**, 19, 413-417	2.3	29
225	Sexual dysfunction in essential hypertension: myth or reality?. *Journal of Clinical Hypertension*, **2006** , 8, 269-74	2.3	29
224	Cardiovascular Outcomes in Action to Control Cardiovascular Risk in Diabetes: Impact of Blood Pressure Level and Presence of Kidney Disease. *American Journal of Nephrology*, **2016**, 43, 271-80	4.6	28
223	Carotid baroreceptor stimulation as a therapeutic target in hypertension and other cardiovascular conditions. *Expert Opinion on Therapeutic Targets*, **2009**, 13, 413-25	6.4	26
222	The interaction of vasoactive substances during exercise modulates platelet aggregation in hypertension and coronary artery disease. *BMC Cardiovascular Disorders*, **2008**, 8, 11	2.3	26
221	Erectile dysfunction in chronic kidney disease: From pathophysiology to management. *World Journal of Nephrology*, **2015**, 4, 379-87	3.6	25
220	Subtype diagnosis, treatment, complications and outcomes of primary aldosteronism and future direction of research: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. *Journal of Hypertension*, **2020**, 38, 1929-1936	1.9	25
219	Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block. *Current Vascular Pharmacology*, **2020**, 18, 172-181	3.3	24
218	The multivalent activity of the tissue factor-thrombin pathway in thrombotic and non-thrombotic disorders as a target for therapeutic intervention. *Expert Opinion on Therapeutic Targets*, **2011**, 15, 75-89	6.4	24
217	Renal sympathetic denervation: renal function concerns. *Hypertension*, **2011**, 58, e19; author reply e20	8.5	24
216	Interventional management of resistant hypertension. *Lancet, The*, **2009**, 373, 1228-30	40	24

215	Orthostatic hypertension: From pathophysiology to clinical applications and therapeutic considerations. *Journal of Clinical Hypertension*, **2019**, 21, 426-433	2.3	23
214	Renal Sympathetic Denervation for the Treatment of Difficult-to-Control or Resistant Hypertension. *International Journal of Hypertension*, **2011**, 2011, 196518	2.4	22
213	Renal sympathetic denervation in hypertension. *Current Opinion in Nephrology and Hypertension*, **2011**, 20, 647-53	3.5	22
212	Renin-Angiotensin System Inhibitors and COVID-19: a Systematic Review and Meta-Analysis. Evidence for Significant Geographical Disparities. *Current Hypertension Reports*, **2020**, 22, 90	4.7	22
211	Carotid baroreceptor activation for the treatment of resistant hypertension and heart failure. *Current Hypertension Reports*, **2012**, 14, 238-46	4.7	21
210	Heart rate recovery, exercise capacity, and mortality risk in male veterans. *European Journal of Preventive Cardiology*, **2012**, 19, 177-84	3.9	21
209	Statin therapy, fitness, and mortality risk in middle-aged hypertensive male veterans. *American Journal of Hypertension*, **2014**, 27, 422-30	2.3	19
208	Carotid baroreceptor stimulation for the treatment of resistant hypertension. *International Journal of Hypertension*, **2011**, 2011, 964394	2.4	19
207	Hyperuricemia as a risk factor for cardiovascular disease. *Expert Review of Cardiovascular Therapy*, **2015**, 13, 19-20	2.5	18
206	The Role of Statins in the Management of Nonalcoholic Fatty Liver Disease. *Current Pharmaceutical Design*, **2018**, 24, 4587-4592	3.3	18
205	Efficacy and safety of renal denervation for the management of arterial hypertension: A systematic review and meta-analysis of randomized, sham-controlled, catheter-based trials. *Journal of Clinical Hypertension*, **2020**, 22, 572-584	2.3	17
204	PDE-5 inhibitors: clinical points. *Current Drug Targets*, **2015**, 16, 420-6	3	17
203	Tissue factor-thrombin signaling enhances the fibrotic activity of myofibroblasts in systemic sclerosis through up-regulation of endothelin receptor A. *Arthritis and Rheumatism*, **2011**, 63, 3586-97		16
202	Liraglutide as Adjunct to Insulin Treatment in Patients with Type 1 Diabetes: A Systematic Review and Meta-analysis. *Current Diabetes Reviews*, **2020**, 16, 313-326	2.7	16
201	COVID19 and increased mortality in African Americans: socioeconomic differences or does the renin angiotensin system also contribute?. *Journal of Human Hypertension*, **2020**, 34, 764-767	2.6	16
200	The European/International Fibromuscular Dysplasia Registry and Initiative (FEIRI)-clinical phenotypes and their predictors based on a cohort of 1000 patients. *Cardiovascular Research*, **2021**, 117, 950-959	9.9	16
199	Lipids, Statins and Heart Failure: An Update. *Current Pharmaceutical Design*, **2016**, 22, 4796-4806	3.3	15
198	Colchicine as a Potential Therapeutic Agent Against Cardiovascular Complications of COVID-19: an Exploratory Review. *SN Comprehensive Clinical Medicine*, **2020**, 2, 1-11	2.7	15

197	Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?. *Open Cardiovascular Medicine Journal*, **2018**, 12, 29-40	0.7	15
196	Prognostic value of arterial stiffness measurements in cardiovascular disease, diabetes, and its complications: The potential role of sodium-glucose co-transporter-2 inhibitors. *Journal of Clinical Hypertension*, **2020**, 22, 562-571	2.3	14
195	The unappreciated importance of blood pressure in recent and older atrial fibrillation trials. *Journal of Hypertension*, **2013**, 31, 2109-17; discussion 2117	1.9	14
194	Halting arterial aging in patients with cardiovascular disease: hypolipidemic and antihypertensive therapy. *Current Pharmaceutical Design*, **2014**, 20, 6339-49	3.3	14
193	Hypertension in Metabolic Syndrome: Novel Insights. *Current Hypertension Reviews*, **2020**, 16, 12-18	2.3	14
192	Heart rate at rest, exercise capacity, and mortality risk in veterans. *American Journal of Cardiology*, **2013**, 112, 1605-9	3	13
191	Platelet activation in essential hypertension during exercise: pre- and post-treatment changes with an angiotensin II receptor blocker. *American Journal of Hypertension*, **2014**, 27, 571-8	2.3	12
190	Time in Therapeutic Range, as a Determinant of All-Cause Mortality in Patients With Hypertension. *Journal of the American Heart Association*, **2017**, 6,	6	12
189	Benefits from treatment and control of patients with resistant hypertension. *International Journal of Hypertension*, **2010**, 2011, 318549	2.4	12
188	SGLT-2 Inhibitors and Cardiovascular Risk in Diabetes Mellitus: A Comprehensive and Critical Review of the Literature. *Current Pharmaceutical Design*, **2017**, 23, 1510-1521	3.3	12
187	Novel Drugs for Hypertension and Heart Failure: Struggling for a Place Under the Sun. *Current Pharmaceutical Design*, **2017**, 23, 1540-1550	3.3	12
186	Dysmetabolic Iron Overload in Metabolic Syndrome. *Current Pharmaceutical Design*, **2020**, 26, 1019-1024	3.3	12
185	Now That Renal Denervation Works, How Do We Proceed?. *Circulation Research*, **2019**, 124, 693-695	15.7	11
184	Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints. *Current Pharmaceutical Design*, **2018**, 24, 1879-1886	3.3	11
183	Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study. *American Journal of Nephrology*, **2017**, 45, 136-145	4.6	10
182	The potential role of statins in treating liver disease. *Expert Review of Gastroenterology and Hepatology*, **2018**, 12, 331-339	4.2	10
181	The impact of frequently encountered cardiovascular risk factors on sexual dysfunction in rheumatic disorders. *Andrology*, **2013**, 1, 556-62	4.2	10
180	Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study. *American Journal of Medicine*, **2017**, 130, 1465.e27-1465.e39	2.4	10

179	Renal and cardiac effects of renal sympathetic denervation and carotid baroreceptor stimulation. *Current Vascular Pharmacology*, **2014**, 12, 55-62	3.3	10
178	Carotid baroreceptor stimulation: a promising approach for the management of resistant hypertension and heart failure. *Current Vascular Pharmacology*, **2014**, 12, 30-7	3.3	10
177	Microalbuminuria is determined by systolic and pulse pressure over a 12-year period and related to peripheral artery disease in normotensive and hypertensive subjects: the Three Areas Study in Greece (TAS-GR). *Angiology*, **2006**, 57, 313-20	2.1	10
176	Different effects of losartan and moxonidine on endothelial function during sympathetic activation in essential hypertension. *Journal of Clinical Hypertension*, **2004**, 6, 682-9	2.3	10
175	SGLT-2 Inhibitors in Type 1 Diabetes Mellitus: A Comprehensive Review of the Literature. *Current Clinical Pharmacology*, **2018**, 13, 261-272	2.5	10
174	Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials. *Diabetes Research and Clinical Practice*, **2019**, 158, 107927	7.4	10
173	Update of the position paper on arterial hypertension and erectile dysfunction. *Journal of Hypertension*, **2020**, 38, 1220-1234	1.9	9
172	Early Vascular Aging Risk Assessment From Ambulatory Blood Pressure Monitoring: The Early Vascular Aging Ambulatory Score. *American Journal of Hypertension*, **2018**, 31, 1197-1204	2.3	9
171	The effect of SGLT2 inhibitors on cardiovascular events and renal function. *Expert Review of Clinical Pharmacology*, **2017**, 10, 1251-1261	3.8	9
170	Sibutramine use associated with reversible hepatotoxicity. *Annals of Internal Medicine*, **2005**, 143, 763-4	8	9
169	Effect of renal sympathetic denervation on short-term blood pressure variability in resistant hypertension: a meta-analysis. *Journal of Hypertension*, **2017**, 35, 1750-1757	1.9	8
168	Hematocrit and Stroke: A Forgotten and Neglected Link?. *Seminars in Thrombosis and Hemostasis*, **2017**, 43, 591-598	5.3	8
167	Sacubitril/valsartan instead of renin-angiotensin system inhibition alone: A step forward in resistant hypertension. *Journal of Clinical Hypertension*, **2018**, 20, 65-68	2.3	8
166	The Co-Existence of NASH and Chronic Kidney Disease Boosts Cardiovascular Risk: Are there any Common Therapeutic Options?. *Current Vascular Pharmacology*, **2018**, 16, 254-268	3.3	8
165	Inflammatory Markers in Cardiovascular Disease; Lessons Learned and Future Perspectives. *Current Vascular Pharmacology*, **2021**, 19, 323-342	3.3	8
164	A Possible Case of Hypertensive Crisis With Intracranial Haemorrhage After an mRNA Anti-COVID-19 Vaccine. *Angiology*, **2022**, 73, 87	2.1	8
163	Microcirculatory function deteriorates with advancing stages of chronic kidney disease independently of arterial stiffness and atherosclerosis. *Hypertension Research*, **2021**, 44, 179-187	4.7	8
162	Impact of Cardiorespiratory Fitness on Mortality in Black Male Veterans With Resistant Systemic Hypertension. *American Journal of Cardiology*, **2017**, 120, 1568-1571	3	7

161	Effect of Low (5 mg) vs. High (20-40 mg) Rosuvastatin Dose on 24h Arterial Stiffness, Central Haemodynamics, and Non-Alcoholic Fatty Liver Disease in Patients with Optimally Controlled Arterial Hypertension. *Current Vascular Pharmacology*, **2018**, 16, 393-400	3.3	7
160	Drugs that Mimic the Effect of Gene Mutations for the Prevention or the Treatment of Atherosclerotic Disease: From PCSK9 Inhibition to ANGPTL3 Inactivation. *Current Pharmaceutical Design*, **2018**, 24, 3638-3646	3.3	7
159	Clinical Value of Measuring the Renin/Aldosterone Levels: Optimising the Management of Uncontrolled/Resistant Hypertension. *Current Vascular Pharmacology*, **2017**, 16, 10-14	3.3	6
158	Hypertension and patients with acute coronary syndrome: Putting blood pressure levels into perspective. *Journal of Clinical Hypertension*, **2019**, 21, 1135-1143	2.3	6
157	Macro and microcirculation damage and incident hypertension: predictors of progression?. *Journal of Hypertension*, **2014**, 32, 1154	1.9	6
156	Bypass of confirmatory tests for case detection of primary aldosteronism in leaner patients?. *Journal of Clinical Hypertension*, **2017**, 19, 798-800	2.3	6
155	Screening for Primary Aldosteronism: Whom and How?. *Journal of Clinical Hypertension*, **2015**, 17, 547-8	2.3	6
154	Erectile dysfunction and adherence to antihypertensive therapy: Focus on β-blockers. *European Journal of Internal Medicine*, **2020**, 81, 1-6	3.9	6
153	Nailfold Capillaroscopy in Systemic Sclerosis Patients with and without Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. *Journal of Clinical Medicine*, **2021**, 10,	5.1	6
152	Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials. *Clinical Rheumatology*, **2021**, 40, 4671-4674	3.9	6
151	Prevalence, Diagnosis, and Treatment with 3 Different Statins of Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis in Military Personnel. Do Genetics Play a Role?. *Current Vascular Pharmacology*, **2021**, 19, 572-581	3.3	6
150	Renal Denervation Therapy for Drug-Resistant Hypertension: Does It Still Work?. *Current Treatment Options in Cardiovascular Medicine*, **2017**, 19, 39	2.1	5
149	Treatment strategies for hypertension in patients with type 1 diabetes. *Expert Opinion on Pharmacotherapy*, **2020**, 21, 1241-1252	4	5
148	Renal Denervation Therapy: Can it Contribute to Better Blood Pressure Control in Hypertension?. *Current Vascular Pharmacology*, **2017**, 16, 66-69	3.3	5
147	Primary aldosteronism in patients with adrenal incidentaloma: Is screening appropriate for everyone?. *Journal of Clinical Hypertension*, **2018**, 20, 942-948	2.3	5
146	Renal Sympathetic Denervation: Hibernation or Resurrection?. *Cardiology*, **2016**, 135, 87-97	1.6	5
145	Non-pharmacological Modulation of the Autonomic Nervous System for Heart Failure Treatment: Where do We Stand?. *Current Vascular Pharmacology*, **2017**, 16, 30-43	3.3	5
144	Leiomyosarcoma of renal vein, initially resembling pheochromocytoma. *Clinical and Experimental Hypertension*, **2012**, 34, 429-31	2.2	5

143	The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 and its Inhibition on Glucose Metabolism and Cardiovascular Risk. We Should do Better the Second Time After Statins. *Current Pharmaceutical Design*, **2017**, 23, 1477-1483	3.3	5
142	Sodium-Glucose Cotransporter‐2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions. *Diabetes Therapy*, **2020**, 11, 3003-3005	3.6	5
141	Erectile Function in Cardiovascular Disease and Hypertension: the Role of Nebivolol. *Journal of Hypertension: Open Access*, **2016**, 05,		5
140	The presence of diabetes mellitus further impairs structural and functional capillary density in patients with chronic kidney disease. *Microcirculation*, **2021**, 28, e12665	2.9	5
139	Dipeptidyl Peptidase-4 Inhibitors and COVID-19-Related Deaths among Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Observational Studies. *Endocrinology and Metabolism*, **2021**, 36, 904-908	3.5	5
138	Right Ventricular Function and Sexual Function: Exploring Shadows in Male and Female Patients With Heart Failure. *Journal of Sexual Medicine*, **2019**, 16, 1199-1211	1.1	4
137	COVID-19: The Waterloo of governments, healthcare systems, and large health organizations. *European Journal of Internal Medicine*, **2020**, 77, 153-155	3.9	4
136	Antihypertensive Drug-Related Side Effects: Is It the Unique Indicator for Nonadherence?. *American Journal of Hypertension*, **2016**, 29, 662	2.3	4
135	What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?. *Current Vascular Pharmacology*, **2019**, 17, 425-428	3.3	4
134	Non-interventional management of resistant hypertension. *World Journal of Cardiology*, **2014**, 6, 1080-90	2.1	4
133	Management of erectile dysfunction: do not forget hypertension. *Archives of Internal Medicine*, **2012**, 172, 597-8; discussion 598		4
132	Mineralocorticoid Receptor Antagonists in Primary Aldosteronism. *Current Pharmaceutical Design*, **2018**, 24, 5508-5516	3.3	4
131	Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease. *Current Vascular Pharmacology*, **2018**, 16, 276-288	3.3	4
130	Risk Scores and Prediction Models in Chronic Heart Failure: A Comprehensive Review. *Current Pharmaceutical Design*, **2021**, 27, 1289-1297	3.3	4
129	Cardiovascular Protection With Sodium-Glucose Cotransporter-2 Inhibitors and Mineralocorticoid Receptor Antagonists in Chronic Kidney Disease: A Milestone Achieved. *Hypertension*, **2021**, 77, 1442-1455	8.5	4
128	Early Anakinra Treatment for COVID-19 Guided by Urokinase Plasminogen Receptor		4
127	Abnormal blood pressure dipping in diabetic kidney disease: A black-race nightmare?. *Journal of Clinical Hypertension*, **2017**, 19, 1336-1338	2.3	3
126	Understanding the cardiovascular risk with non-insulin antidiabetic drugs. *Expert Opinion on Drug Safety*, **2019**, 18, 241-251	4.1	3

125	Pharmacological Management of Cardiac Disease in Patients with Type 2 Diabetes: Insights into Clinical Practice. *Current Vascular Pharmacology*, **2020**, 18, 125-138	3.3	3
124	Carotid intima-media thickness as a target-organ damage and treatment-target: Need for a major revision?. *Journal of Clinical Hypertension*, **2018**, 20, 255-257	2.3	3
123	Renal nerve ablation for resistant hypertension: the dust has not yet settled. *Journal of Clinical Hypertension*, **2014**, 16, 399-400	2.3	3
122	Renal denervation: transition from pathophysiology to clinical practice. *Angiology*, **2014**, 65, 760-8	2.1	3
121	Effects of hypertension and antihypertensive therapy on sexual function in the elderly: the jury is still out. *Journal of Hypertension*, **2013**, 31, 1917-8	1.9	3
120	Surgical management of primary aldosteronism. not everything that shines is gold. *Clinical and Experimental Hypertension*, **2012**, 34, 53-6	2.2	3
119	Treatment strategies to prevent stroke: focus on optimal lipid and blood pressure control. *Expert Opinion on Pharmacotherapy*, **2009**, 10, 955-66	4	3
118	Intracerebral hemorrhage as the presenting feature of concurrent pheochromocytoma and paragangliomas. *Journal of Clinical Hypertension*, **2008**, 10, 941-4	2.3	3
117	Recent advances in understanding and managing resistant/refractory hypertension. *F1000Research* , **2020**, 9,	3.6	3
116	Assessment of skin microcirculation in primary aldosteronism: impaired microvascular responses compared to essential hypertensives and normotensives. *Journal of Human Hypertension*, **2021**,	2.6	3
115	Comparison of ambulatory central hemodynamics and arterial stiffness in patients with diabetic and non-diabetic CKD. *Journal of Clinical Hypertension*, **2020**, 22, 2239-2249	2.3	3
114	Exercise blood pressure, cardiorespiratory fitness and mortality risk. *Progress in Cardiovascular Diseases*, **2021**, 67, 11-17	8.5	3
113	Primary Aldosteronism: Novel Insights. *Current Hypertension Reviews*, **2020**, 16, 19-23	2.3	3
112	Meta-analysis Evaluating the Risk of Atrial Fibrillation With Newer Antidiabetics Across the Cardiovascular and Renal Outcome Trials. *American Journal of Cardiology*, **2021**, 139, 139-141	3	3
111	Peripheral microcirculatory abnormalities are associated with cardiovascular risk in systemic sclerosis: a nailfold video capillaroscopy study. *Clinical Rheumatology*, **2021**, 40, 4957-4968	3.9	3
110	Beneficial effects of sodium glucose co-transporter 2 inhibitors (SGLT2i) on heart failure and cardiovascular death in patients with type 2 diabetes might be due to their off-target effects on cardiac metabolism. *Clinical Lipidology*, **2016**, 11, 2-5		3
109	Insomnia and hypertension: A misty landscape. *Journal of Clinical Hypertension*, **2019**, 21, 835-837	2.3	2
108	Subclinical target organ damage in primary aldosteronism: resistant to spironolactone therapy?. *Journal of Hypertension*, **2018**, 36, 701	1.9	2

107	Renal sympathetic denervation: Ashes to ashes or rebirth from the ashes?. *Journal of Clinical Hypertension*, **2018**, 20, 634-636	2.3	2
106	Peripheral arterial stiffness as a surrogate of central hemodynamics: A new era for cardiovascular risk estimation?. *Journal of Clinical Hypertension*, **2018**, 20, 469-471	2.3	2
105	Evaluation, risk stratification and management of hypertensive patients in the perioperative period. *European Journal of Internal Medicine*, **2019**, 69, 1-7	3.9	2
104	Telmisartan for prevention of cardiovascular events. *New England Journal of Medicine*, **2009**, 360, 302; author reply 303	59.2	2
103	A graded association of exercise capacity and all-cause mortality in males with high-normal blood pressure. *Blood Pressure*, **2009**, 18, 261-267	1.7	2
102	Letter by Triantafyllou et al regarding article, "Mild retinopathy is a risk factor for cardiovascular mortality in Japanese with and without hypertension: the Ibaraki Prefectural Health Study". *Circulation*, **2012**, 126, e12; author reply e14	16.7	2
101	Recent advances in the management of resistant hypertension. *F1000prime Reports*, **2015**, 7, 03		2
100	LDL cholesterol target achievement in heterozygous familial hypercholesterolemia patients according to 2019 ESC/EAS lipid guidelines: Implications for newer lipid-lowering treatments. *International Journal of Cardiology*, **2021**, 345, 119-124	3.2	2
99	Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors: A meta-analysis of cardiovascular outcome trials. *World Journal of Cardiology*, **2021**, 13, 585-592	2.1	2
98	Erectile Dysfunction as a Cardiovascular Risk Factor: Time to Step Up?. *Current Vascular Pharmacology*, **2021**, 19, 301-312	3.3	2
97	Macro and microcirculation damage and incident hypertension. *Journal of Hypertension*, **2014**, 32, 1154	1.9	2
96	Left Ventricular Hypertrophy and Mortality Risk in Male Veteran Patients at High Cardiovascular Risk. *American Journal of Cardiology*, **2020**, 125, 887-893	3	2
95	Time to assess the effects of sodium-glucose co-transporter-2 inhibitors on the forgotten right ventricle?. *ESC Heart Failure*, **2020**, 7, 337-338	3.7	2
94	Meta-analysis Assessing the Effect of Sodium-Glucose Co-transporter-2 Inhibitors on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus. *American Journal of Cardiology*, **2020**, 134, 149-152	3	2
93	Renal tubular transport protein regulation in primary aldosteronism: can large-scale proteomic analysis offer a new insight?. *Journal of Human Hypertension*, **2021**, 35, 825-827	2.6	2
92	Updated meta-analysis assessing the risk of amputation with sodium-glucose co-transporter-2 inhibitors in the hallmark cardiovascular and renal outcome trials. *Diabetes, Obesity and Metabolism*, **2021**, 23, 1063-1065	6.7	2
91	The effect of glucagon-like peptide-1 receptor agonists on 24-hour ambulatory blood pressure: a confirmatory meta-analysis. *Blood Pressure Monitoring*, **2021**, 26, 284-287	1.3	2
90	Sodium-glucose Cotransporter 2 Inhibitors: Nephroprotective Impact on Diabetic Kidney Disease. *Cardiovascular & Hematological Disorders Drug Targets*, **2018**, 18, 120-126	1.1	2

89	Patients with autoimmune chronic inflammatory diseases present increased biomarkers of thromboinflammation and endothelial dysfunction in the absence of flares and cardiovascular comorbidities. *Journal of Thrombosis and Thrombolysis*, **2021**, 1	5.1	2
88	Updated Meta-Analysis of Cardiovascular Outcome Trials Evaluating Cardiovascular Efficacy of Glucagon-Like Peptide-1 Receptor Agonists. *American Journal of Cardiology*, **2021**, 159, 143-146	3	2
87	Blood pressure and cardiovascular outcomes: a closer look. *Lancet, The*, **2017**, 389, 1295-1296	40	1
86	Acute heart failure, type 2 diabetes and loop diuretic use: any adjunct role for sodium-glucose cotransporter-2 inhibitors?. *Journal of Cardiovascular Medicine*, **2020**, 21, 343	1.9	1
85	Renal resistive index for renovascular hypertension: In the quest of the Holy Grail. *Journal of Clinical Hypertension*, **2018**, 20, 589-591	2.3	1
84	Primary Aldosteronism: A Field on the Move. *Updates in Hypertension and Cardiovascular Protection*, **2016**, 29-55	0.1	1
83	Depression in hypertensive patients: the role of comorbidities. *Journal of Hypertension*, **2016**, 34, 1441	1.9	1
82	Exaggerated Blood Pressure Response to Exercise: Will It Ever Be Ready for Prime Time?. *Journal of Clinical Hypertension*, **2015**, 17, 845-7	2.3	1
81	Prehypertension and the cardiometabolic syndrome: targeting several risk factors to achieve maximum benefit. *Expert Review of Cardiovascular Therapy*, **2014**, 12, 295-6	2.5	1
80	Antihypertensive therapy after acute ischemic stroke. *JAMA - Journal of the American Medical Association*, **2014**, 311, 2333-4	27.4	1
79	Platelet activation during exercise is not attenuated by inhibition of the renin-angiotensin system: the role of physical activity. *Journal of Hypertension*, **2013**, 31, 2103	1.9	1
78	Effects of antihypertensive therapy on female sexual dysfunction: clinically meaningful?. *Journal of Hypertension*, **2012**, 30, 1263-4; author reply 1264-5	1.9	1
77	Epicardial adipose tissue: does it mediate the cardio-protective effects of sodium-glucose co-transporter 2 inhibitors in patients with heart failure? Letter regarding the article Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure. *European Journal of Heart Failure*, **2022**	12.3	1
76	Meta-Analysis of Randomized Controlled Trials Evaluating the Effect of Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Receptor Agonists on Blood Pressure Levels in Patients With Type 2 Diabetes Mellitus.. *American Journal of Cardiology*, **2021**,	3	1
75	Meta-Analysis Addressing the Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Flow-Mediated Dilation in Patients With Type 2 Diabetes Mellitus. *American Journal of Cardiology*, **2021**,	3	1
74	Updated Meta-Analysis Evaluating the Beneficial Effects of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Heart Failure. *American Journal of Cardiology*, **2021**, 161, 118-120	3	1
73	Is there any place for sodium-glucose co-transporter-2 inhibitors in post-liver transplantation patients?. *Digestive and Liver Disease*, **2020**, 52, 239-240	3.3	1
72	Updated Meta-analysis Assessing the Effect of Sodium-Glucose Co-transporter-2 Inhibitors on Surrogate End points in Patients With Heart Failure With Reduced Ejection Fraction. *American Journal of Cardiology*, **2020**, 137, 130-132	3	1

71	Updated Meta-Analysis of Trials Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Black Patients. *American Journal of Cardiology*, **2020**, 137, 133-135	3	1
70	Sodium-glucose co-transporter-2 inhibitors and arterial stiffness: Class effect or drug effect?. *Journal of Clinical Hypertension*, **2020**, 22, 2389-2390	2.3	1
69	Meta-analysis of the hallmark cardiovascular and renal outcome trials addressing the risk for respiratory tract infections with sodium-glucose co-transporter-2 inhibitors: Implications for the COVID-19 pandemic. *Diabetes, Obesity and Metabolism*, **2021**, 23, 1696-1700	6.7	1
68	Joint ESH excellence centersO national meeting on renal sympathetic denervation: A Greek expertsO survey. *Hellenic Journal of Cardiology*, **2021**, 62, 355-358	2.1	1
67	Chronic kidney disease and diabetes status do not affect efficacy of SGLT-2 inhibitors in patients with heart failure with reduced ejection fraction. *European Journal of Internal Medicine*, **2021**, 87, 100-101	3.9	1
66	Glucagon-like Peptide-1 Receptor Agonists and the Risk of Acute Kidney Injury: Alarming, or Not?. *Kidney Medicine*, **2021**, 3, 674-675	2.8	1
65	Approach to Erectile Dysfunction in Patients with Hypertension and Coronary Artery Disease **2016**, 309-327		1
64	Sodium-glucose co-transporter-2 inhibitors, cardiovascular outcomes and the impact of gender: Class effect or statistical play of chance?. *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*, **2020**, 14, 347	8.9	1
63	Meta-Analysis Assessing the Effects of Allopurinol on Left Ventricular Mass and Other Indices of Left Ventricular Remodeling as Evaluated by Cardiac Magnetic Resonance Imaging. *American Journal of Cardiology*, **2021**, 138, 129-132	3	1
62	Surrogate cardiovascular outcomes with sodium-glucose co-transporter-2 inhibitors in women: An updated meta-analysis. *Indian Heart Journal*, **2021**, 73, 132-134	1.6	1
61	Antihypertensive drug treatment: the real-life challenge. *Journal of Clinical Hypertension*, **2018**, 20, 115-117	2.3	1
60	Serum uric acid lowering mediated by glucagon-like peptide-1 receptor agonists: Emerging considerations.. *British Journal of Clinical Pharmacology*, **2022**,	3.8	1
59	Hypertension and hyperhomocysteinemia as risk factors for chronic kidney disease: A dangerous duo?. *Journal of Clinical Hypertension*, **2019**, 21, 1578-1579	2.3	0
58	Testosterone Replacement Therapy and Cardiovascular Risk-A Closer Look at Additional Parameters. *JAMA Internal Medicine*, **2017**, 177, 1393	11.5	0
57	Meta-Analysis Assessing the Impact of Previous Heart Failure and Chronic Kidney Disease on the Cardiovascular Efficacy of Glucagon-Like Peptide-1 Receptor Agonists.. *American Journal of Cardiology*, **2022**,	3	0
56	Sodium-Glucose Co-Transporter-2 Inhibitors Decrease the Odds for Atrial Fibrillation in Subjects with Heart Failure.. *Journal of Stroke and Cerebrovascular Diseases*, **2021**, 106257	2.8	0
55	Digital Biomarkers for Supporting Transitional Care Decisions: Protocol for a Transnational Feasibility Study.. *JMIR Research Protocols*, **2022**, 11, e34573	2	0
54	Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated "enemy"?. *Clinical and Molecular Hepatology*, **2020**, 26, 582-583	6.9	0

53	Effect of empagliflozin on cholesterol synthesis and absorption markers in patients with type 2 diabetes: Any role of DPP-4 inhibitors?. *International Journal of Cardiology*, **2021**, 330, 228	3.2	0
52	Opportunistic screening for hypertension in the general population in Greece: International Society of Hypertension May Measurement Month 2019. *European Heart Journal Supplements*, **2021**, 23, B66-B69	1.5	0
51	Sodium-glucose co-transporter-2 inhibitors and sacubitril/valsartan combination in patients with heart failure with reduced ejection fraction; does it deserve our attention?. *American Heart Journal*, **2021**, 236, 104-105	4.9	0
50	Letter to the Editor: Sodium-Glucose Cotransporter 2 Inhibitors Ameliorate Ascites and Peripheral Edema in Patients With Cirrhosis and Diabetes. *Hepatology*, **2021**, 73, 866	11.2	0
49	Sodium-glucose co-transporter-2 inhibitor and glucagon-like peptide-1 receptor agonist combination treatment: Promising, but shall we look at other indices?. *International Journal of Cardiology*, **2021**, 323, 259	3.2	0
48	Meta-analysis of Dedicated Renal Outcome Trials Assessing the Cardio-renal Efficacy of Sodium-Glucose Co-transporter-2 Inhibitors in Patients With Chronic Kidney Disease and Albuminuria. *American Journal of Cardiology*, **2021**, 138, 116-118	3	0
47	Meta-Analysis Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors According to Baseline Treatment of Interest. *American Journal of Cardiology*, **2021**, 139, 134-136	3	0
46	Torasemide in Hypertension and Heart Failure: Re-inventing Loop Diuretic Therapy?. *Current Pharmaceutical Design*, **2021**, 27, 2714-2721	3.3	0
45	Impact of renal sympathetic denervation on cardiac magnetic resonance-derived cardiac indices in hypertensive patients - A meta-analysis. *Journal of Cardiology*, **2021**, 78, 314-321	3	0
44	Association between lipoprotein(a) concentrations and atherosclerotic cardiovascular disease risk in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH.. *Endocrine*, **2022**, 1	4	0
43	Meta-Analysis Assessing the Effect of Tirzepatide on the Risk for Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus.. *American Journal of Cardiology*, **2022**,	3	0
42	Impact of Primary Aldosteronism in Resistant Hypertension.. *Current Hypertension Reports*, **2022**, 1	4.7	0
41	Meta-Analysis Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Chronic Obstructive Pulmonary Disease.. *American Journal of Cardiology*, **2022**,	3	0
40	Physical Activity, Fitness, and Sexual Dysfunction **2019**, 373-387		
39	Arterial and liver stiffness in patients with non-alcoholic fatty liver disease: hitting two targets with sodium-glucose co-transporter-2 inhibitors. *European Journal of Gastroenterology and Hepatology*, **2020**, 32, 460-461	2.2	
38	Pericardial fat in type 2 diabetes: not just a biomarker, but a promising treatment target?. *Acta Diabetologica*, **2020**, 57, 905-906	3.9	
37	PATHWAY-2: spironolactone for resistant hypertension. *Lancet, The*, **2016**, 387, 1371-1372	40	
36	Discontinuation of Antihypertensive Treatment in Elderly Patients and Cognitive Function. *JAMA Internal Medicine*, **2016**, 176, 409	11.5	

35	Statin and exercise prescription - AuthorsOreply. *Lancet, The*, **2013**, 381, 1622-3	40
34	Masked hypertension in untreated and treated patients with diabetes mellitus: attractive but questionable interpretations. *Hypertension*, **2013**, 62, e21	8.5
33	Pheochromocytoma: ???The Great Mimic??? **2008**, 18, 121-123	
32	Meta-Analysis of Randomized Controlled Trials Evaluating the Efficacy of Polymer-Free Amphilimus-Eluting Stents in Coronary Artery Disease.. *American Journal of Cardiology*, **2022**,	3
31	Colchicine for the prevention of COVID-19 "hard" outcomes: All that glitters is not gold. *European Journal of Internal Medicine*, **2021**,	3.9
30	Endothelial dysfunction and COVID-19: What the true impact on surrogate outcomes?. *International Journal of Cardiology*, **2021**,	3.2
29	Meta-Analysis of Dedicated Heart Failure Trials Evaluating the Effect of Sacubitril/Valsartan on Major Cardiac Rhythm Disorders. *American Journal of Cardiology*, **2021**, 161, 120-122	3
28	Febuxostat versus allopurinol for patients with gout: is it time to overcome concerns regarding cardiovascular safety?. *Reumatologia*, **2021**, 59, 423-424	1.7
27	Net benefit regarding the risk for death with sodium-glucose co-transporter-2 inhibitors across the hallmark cardiovascular and renal outcome trials; are there any drug differences?. *Journal of Diabetes and Metabolic Disorders*,1	2.5
26	Use of corticosteroids in SARS-CoV-2 infection: foe, or can they become a friend?. *Polish Archives of Internal Medicine*, **2020**, 130, 922	1.9
25	Cardiovascular drug therapy and surrogate COVID-19 outcomes: which is the impact of the "miraculous" sodium-glucose co-transporter-2 inhibitors?. *Kardiologia Polska*, **2021**, 79, 1048-1049	0.9
24	Letter: Effects of Dapagliflozin on Endothelial Function, Renal Injury Markers, and Glycemic Control in Drug-Naïve Patients with Type 2 Diabetes Mellitus (2019:43:711-7). *Diabetes and Metabolism Journal*, **2019**, 43, 906-908	5
23	Serum leptin in non-alcoholic fatty liver disease: Ambiguous clinical implications concerning cardiovascular disease. *Clinical and Molecular Hepatology*, **2019**, 25, 331-332	6.9
22	Pentraxin 3 in patients with type 2 diabetes and nonalcoholic fatty liver disease: a promising treatment target for glucagon-like peptide-1 receptor agonists. *Polish Archives of Internal Medicine*, **2019**, 129, 648-649	1.9
21	Meta-Analysis Assessing the Impact of Major Co-Morbidities, Gender, and Race on Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors Among Patients With Heart Failure With Preserved or Reduced Ejection Fraction. *American Journal of Cardiology*, **2021**,	3
20	Sympathetic Renal Denervation Using the EnligHTN Multi-electrode Ablation System: The St Jude Experience **2015**, 69-79	
19	Arterial Stiffness and Nonalcoholic Fatty Liver Disease: Which is the Chicken and Which is the Egg?. *Open Hypertension Journal*, **2017**, 9, 1-5	0.8
18	Sexual Function in Untreated and Treated Hypertension **2012**, 389-398	

17	Coronary artery disease, arterial stiffness, and myocardial work: what is the role of diabetes in this vicious circle?. *Kardiologia Polska*, **2021**, 79, 360	0.9
16	Acute hyperglycemic crises with sodium-glucose co-transporter-2 inhibitors across the cardiovascular and renal outcome trials: An anticipated fear?. *Endocrinologia, Diabetes Y Nutrici*, **2021**,	1.3
15	Female Sexual Dysfunction: A Problem Hidden in the Shadows. *Current Pharmaceutical Design*, **2021** , 27, 3762-3774	3.3
14	Selecting Optimum Antihypertensive Therapy **2016**, 217-247	
13	Renal Denervation: A Historical Perspective. *Updates in Hypertension and Cardiovascular Protection*, **2016**, 201-213	0.1
12	Fitness: The "Secret" of Vascular Youth. *Journal of Clinical Hypertension*, **2016**, 18, 290-1	2.3
11	New data, new studies, new hopes for renal denervation in patients with uncontrolled hypertension. *International Journal of Cardiology: Hypertension*, **2019**, 3, 100022	1.6
10	The VA Co-operative Studies; The First RCTs in Cardiovascular Disease A Tribute to Edward D. Freis **2019**, 75-88	
9	Metabolic syndrome: joint diagnostic criteria and links with comorbidities. *Hormones*, **2019**, 18, 107-108	3.1
8	Prehypertension, the Risk of Hypertension and Events. *Updates in Hypertension and Cardiovascular Protection*, **2019**, 37-55	0.1
7	Diabetes mellitus and SARS-CoV-2-related mortality: the impact of acute hyperglycemic crises and some further considerations. *Acta Diabetologica*, **2021**, 58, 125-126	3.9
6	The Role of Bariatric Surgery in Prevention of Kidney Disease Progression in Moderately Obese Patients With Type 2 Diabetes. *JAMA Surgery*, **2021**, 156, 204	5.4
5	Prevalence of Non-coronary Heart Disease in Patients with Familial Hypercholesterolemia: An Analysis from the HELLAS-FH. *Current Pharmaceutical Design*, **2021**, 27, 2537-2544	3.3
4	Meta-Analysis Addressing the Effect of Mineralcorticoid Receptor Antagonists on the Risk for New-Onset Atrial Fibrillation. *American Journal of Cardiology*, **2021**, 157, 150-152	3
3	"SGLT2i in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients series" comment.. *Internal and Emergency Medicine*, **2022**,	3.7
2	Meta-Analysis Evaluating the Effect of Sodium-Glucose Co-Transporter-2 Inhibitors on Pulmonary Artery Pressure Indices.. *American Journal of Cardiology*, **2022**,	3
1	"Which one should I choose, a glucagon-like peptide-1 receptor agonist or a sodium-glucose cotransporter 2 inhibitor? Or maybe both?". *European Journal of Internal Medicine*, **2021**,	3.9